ArticleToxicology research2025
Exploring the causal relationship and molecular mechanisms between Methyl-4-hydroxybenzoic acid (MEP) and Alzheimer's disease: a mendelian randomization, multi-omics, and network toxicology approach.
Article in Toxicology research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The pathogenesis of Alzheimer's disease remains incompletely understood. Methyl-4-hydroxybenzoic acid, a common chemical additive, may play a role, though its mechanisms are unclear. This research investigated the potential causal link between Methyl-4-hydroxybenzoic acid and Alzheimer's disease and examined underlying molecular mechanisms. Mendelian randomization analysis evaluated causality, using Cochran's Q test, the Mendelian Randomization-Egger intercept test, and Mendelian Randomization Pleiotropy RESidual Sum and Outlier to assess heterogeneity and sensitivity. Methyl-4-hydroxybenzoic acid targets were identified through multiple databases, and a related target library was constructed using Weighted Gene Co-expression Network Analysis, differential gene expression analysis, and the Genecards database. A Protein-Protein Interaction network identified core genes, validated by molecular docking. Transcriptomic analysis and single-cell expression data explored cell-type-specific expression patterns. Results showed a significant positive causal association between Methyl-4-hydroxybenzoic acid and Alzheimer's disease. We identified 198 Methyl-4-hydroxybenzoic acid targets, with 99 genes associated with both Methyl-4-hydroxybenzoic acid and Alzheimer's disease. Six core genes (EGFR, ESR1, MAPK3, MMP9, PTGS2, TP53) were pinpointed. Functional enrichment implicated neuronal signaling, inflammation, and metabolism. Multi-omics and single-cell analyses revealed differential expression of core genes in key brain regions. Molecular docking confirmed stable interactions between Methyl-4-hydroxybenzoic acid and these proteins. This research confirms a causal relationship between Methyl-4-hydroxybenzoic acid and Alzheimer's disease, revealing potential molecular mechanisms and core gene functions, offering insights into pathogenesis and therapeutic targets.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.